These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36935853)

  • 61. Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMAT.
    de Chavez R; Grogan G; Hug B; Howe K; Grigg A; Waterhouse D; Lane J; Glyde A; Brown E; Bydder S; Pryor D; Hargrave C; Charles PH; Hellyer J; Ebert MA
    Med Dosim; 2022 Spring; 47(1):61-69. PubMed ID: 34551879
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Focal salvage treatment for radiorecurrent prostate cancer: A magnetic resonance-guided stereotactic body radiotherapy versus high-dose-rate brachytherapy planning study.
    Willigenburg T; Beld E; Hes J; Lagendijk JJW; de Boer HCJ; Moerland MA; van der Voort van Zyp JRN
    Phys Imaging Radiat Oncol; 2020 Jul; 15():60-65. PubMed ID: 33458327
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dosimetric effect of the intestinal gas of online adaptive stereotactic body radiotherapy on target and critical organs without online electron density correction for pancreatic cancer.
    Su C; Okamoto H; Nishioka S; Sakasai T; Fujiyama D; Miura Y; Tsunoda Y; Kuwahara J; Nakamura S; Iijima K; Chiba T; Kaga K; Takemori M; Nakayama H; Katsuta S; Inaba K; Igaki H; Nakayama Y; Itami J
    Br J Radiol; 2021 Mar; 94(1119):20200239. PubMed ID: 33353402
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Individual lymph nodes: "See it and Zap it".
    Winkel D; Werensteijn-Honingh AM; Kroon PS; Eppinga WSC; Bol GH; Intven MPW; de Boer HCJ; Snoeren LMW; Hes J; Raaymakers BW; Jürgenliemk-Schulz IM
    Clin Transl Radiat Oncol; 2019 Sep; 18():46-53. PubMed ID: 31341975
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
    Henke LE; Stanley JA; Robinson C; Srivastava A; Contreras JA; Curcuru A; Green OL; Massad LS; Kuroki L; Fuh K; Hagemann A; Mutch D; McCourt C; Thaker P; Powell M; Markovina S; Grigsby PW; Schwarz JK; Chundury A
    Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):379-389. PubMed ID: 34474109
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identifying predictors of on-table adaptation for pancreas stereotactic body radiotherapy (SBRT).
    Wu TC; Yoon SM; Cao M; Raldow AC; Xiang M
    Clin Transl Radiat Oncol; 2023 May; 40():100603. PubMed ID: 36896266
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of intrafraction motion in pancreatic cancer treatments with MR-guided adaptive radiation therapy.
    Rusu DN; Cunningham JM; Arch JV; Chetty IJ; Parikh PJ; Dolan JL
    Front Oncol; 2023; 13():1298099. PubMed ID: 38162503
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined Inter- and Intrafractional Plan Adaptation Using Fraction Partitioning in Magnetic Resonance-guided Radiotherapy Delivery.
    Lagerwaard F; Bohoudi O; Tetar S; Admiraal MA; Rosario TS; Bruynzeel A
    Cureus; 2018 Apr; 10(4):e2434. PubMed ID: 29876156
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
    Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
    Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
    [No Abstract]   [Full Text] [Related]  

  • 70. Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours.
    Hoffmann L; Persson GF; Nygård L; Nielsen TB; Borrisova S; Gaard-Petersen F; Josipovic M; Khalil AA; Kjeldsen R; Knap MM; Kristiansen C; Møller DS; Ottosson W; Sand H; Thing R; Pøhl M; Schytte T
    Radiother Oncol; 2022 Jun; 171():53-61. PubMed ID: 35421513
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Simulated computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of locally advanced pancreatic cancer.
    Schiff JP; Price AT; Stowe HB; Laugeman E; Chin RI; Hatscher C; Pryser E; Cai B; Hugo GD; Kim H; Badiyan SN; Robinson CG; Henke LE
    Radiother Oncol; 2022 Oct; 175():144-151. PubMed ID: 36063981
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy.
    Tyran M; Jiang N; Cao M; Raldow A; Lamb JM; Low D; Luterstein E; Steinberg ML; Lee P
    Radiother Oncol; 2018 Nov; 129(2):319-325. PubMed ID: 30174107
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improved Ipsilateral Breast and Chest Wall Sparing With MR-Guided 3-fraction Accelerated Partial Breast Irradiation: A Dosimetric Study Comparing MR-Linac and CT-Linac Plans.
    Musunuru HB; Yadav P; Olson SJ; Anderson BM
    Adv Radiat Oncol; 2021; 6(3):100654. PubMed ID: 34195491
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Full automation of spinal stereotactic radiosurgery and stereotactic body radiation therapy treatment planning using Varian Eclipse scripting.
    Teruel JR; Malin M; Liu EK; McCarthy A; Hu K; Cooper BT; Sulman EP; Silverman JS; Barbee D
    J Appl Clin Med Phys; 2020 Oct; 21(10):122-131. PubMed ID: 32965754
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Organ-at-risk dose prediction using a machine learning algorithm: Clinical validation and treatment planning benefit for lung SBRT.
    Brodin NP; Schulte L; Velten C; Martin W; Shen S; Shen J; Basavatia A; Ohri N; Garg MK; Carpenter C; Tomé WA
    J Appl Clin Med Phys; 2022 Jun; 23(6):e13609. PubMed ID: 35460150
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non‒small-cell lung cancer or lung metastases.
    Chi A; Jang SY; Welsh JS; Nguyen NP; Ong E; Gobar L; Komaki R
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):856-62. PubMed ID: 21255942
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART).
    Lee G; Han Z; Huynh E; Tjong MC; Cagney DN; Huynh MA; Kann BH; Kozono D; Leeman JE; Singer L; Williams CL; Mak RH
    Radiother Oncol; 2024 Jan; 190():110034. PubMed ID: 38030080
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Effect of Various Dose Normalization Strategies When Implementing Linear Boltzmann Transport Equation Dose Calculation for Lung Stereotactic Body Radiation Therapy Planning.
    Erickson BG; Ackerson BG; Kelsey CR; Yin FF; Adamson J; Cui Y
    Pract Radiat Oncol; 2022; 12(5):446-456. PubMed ID: 35219882
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dosimetric study for spine stereotactic body radiation therapy: magnetic resonance guided linear accelerator versus volumetric modulated arc therapy.
    Yadav P; Musunuru HB; Witt JS; Bassetti M; Bayouth J; Baschnagel AM
    Radiol Oncol; 2019 Sep; 53(3):362-368. PubMed ID: 31553704
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
    König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
    Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.